BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 15186263)

  • 1. Natural killer T cells as targets for immunotherapy of autoimmune diseases.
    Van Kaer L
    Immunol Cell Biol; 2004 Jun; 82(3):315-22. PubMed ID: 15186263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of immune responses by CD1d-restricted natural killer T cells.
    Van Kaer L
    Immunol Res; 2004; 30(2):139-53. PubMed ID: 15477656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.
    Singh AK; Wilson MT; Hong S; Olivares-Villagómez D; Du C; Stanic AK; Joyce S; Sriram S; Koezuka Y; Van Kaer L
    J Exp Med; 2001 Dec; 194(12):1801-11. PubMed ID: 11748281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy.
    Yu KO; Porcelli SA
    Immunol Lett; 2005 Aug; 100(1):42-55. PubMed ID: 16083968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.
    Godó M; Sessler T; Hamar P
    Curr Med Chem; 2008; 15(18):1778-87. PubMed ID: 18691038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunoregulatory role of CD1d-restricted natural killer T cells in disease.
    van der Vliet HJ; Molling JW; von Blomberg BM; Nishi N; Kölgen W; van den Eertwegh AJ; Pinedo HM; Giaccone G; Scheper RJ
    Clin Immunol; 2004 Jul; 112(1):8-23. PubMed ID: 15207777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer T cells and autoimmune disease.
    Wu L; Van Kaer L
    Curr Mol Med; 2009 Feb; 9(1):4-14. PubMed ID: 19199937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of natural killer T cells in antitumor immunotherapy.
    Hong C; Park SH
    Crit Rev Immunol; 2007; 27(6):511-25. PubMed ID: 18197797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of hepatic NKT cells and subsequent liver injury following administration of alpha-galactosylceramide.
    Osman Y; Kawamura T; Naito T; Takeda K; Van Kaer L; Okumura K; Abo T
    Eur J Immunol; 2000 Jul; 30(7):1919-28. PubMed ID: 10940881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iNKT-cell responses to glycolipids.
    Parekh VV; Wilson MT; Van Kaer L
    Crit Rev Immunol; 2005; 25(3):183-213. PubMed ID: 16048435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative and qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-anomeric glycolipids.
    Parekh VV; Singh AK; Wilson MT; Olivares-Villagómez D; Bezbradica JS; Inazawa H; Ehara H; Sakai T; Serizawa I; Wu L; Wang CR; Joyce S; Van Kaer L
    J Immunol; 2004 Sep; 173(6):3693-706. PubMed ID: 15356115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.
    Wilson MT; Van Kaer L
    Curr Pharm Des; 2003; 9(3):201-20. PubMed ID: 12570826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
    Fujii S; Shimizu K; Hemmi H; Steinman RM
    Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice.
    Cardell SL
    Clin Exp Immunol; 2006 Feb; 143(2):194-202. PubMed ID: 16412042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype.
    Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L
    J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of γδ T cells in α-galactosylceramide-mediated immunity.
    Paget C; Chow MT; Duret H; Mattarollo SR; Smyth MJ
    J Immunol; 2012 Apr; 188(8):3928-39. PubMed ID: 22412194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune Type 1 diabetes.
    Sharif S; Arreaza GA; Zucker P; Mi QS; Sondhi J; Naidenko OV; Kronenberg M; Koezuka Y; Delovitch TL; Gombert JM; Leite-De-Moraes M; Gouarin C; Zhu R; Hameg A; Nakayama T; Taniguchi M; Lepault F; Lehuen A; Bach JF; Herbelin A
    Nat Med; 2001 Sep; 7(9):1057-62. PubMed ID: 11533711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic activation of Valpha24+Vbeta11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity.
    Nieda M; Okai M; Tazbirkova A; Lin H; Yamaura A; Ide K; Abraham R; Juji T; Macfarlane DJ; Nicol AJ
    Blood; 2004 Jan; 103(2):383-9. PubMed ID: 14512316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoregulation of autoimmunity by natural killer T cells.
    Linsen L; Somers V; Stinissen P
    Hum Immunol; 2005 Dec; 66(12):1193-202. PubMed ID: 16690406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD1d-restricted help to B cells by human invariant natural killer T lymphocytes.
    Galli G; Nuti S; Tavarini S; Galli-Stampino L; De Lalla C; Casorati G; Dellabona P; Abrignani S
    J Exp Med; 2003 Apr; 197(8):1051-7. PubMed ID: 12695492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.